InMed Pharmaceuticals Inc.
INM
$2.96
$0.24378.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -12.09% | -1.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.09% | -1.44% | |||
| Cost of Revenue | -15.61% | -5.61% | |||
| Gross Profit | -6.59% | 5.86% | |||
| SG&A Expenses | 9.26% | 17.13% | |||
| Depreciation & Amortization | -2.56% | -0.36% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.91% | -8.30% | |||
| Operating Income | -25.77% | 12.68% | |||
| Income Before Tax | -53.47% | 13.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -53.47% | 13.41% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -53.47% | 13.41% | |||
| EBIT | -25.77% | 12.68% | |||
| EBITDA | -26.68% | 13.02% | |||
| EPS Basic | -34.70% | 32.98% | |||
| Normalized Basic EPS | -34.69% | 32.74% | |||
| EPS Diluted | -34.70% | 32.98% | |||
| Normalized Diluted EPS | -34.69% | 32.74% | |||
| Average Basic Shares Outstanding | 13.93% | 29.21% | |||
| Average Diluted Shares Outstanding | 13.93% | 29.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||